Drugs / CGB-400
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04508205 | Oct 2018 → Apr 2019 | rosacea | CAGE Bio Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04508660 | Oct 2018 → Apr 2019 | rosacea | CAGE Bio Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04886739 | May → Dec 2021 | rosacea | CAGE Bio Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGB-400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04886739 ↗ |
| Route | Topical | “Topical administration twice daily for 12 weeks” NCT04508205 ↗ |